CA3014001A1 - Binding members to pd-l1 - Google Patents

Binding members to pd-l1 Download PDF

Info

Publication number
CA3014001A1
CA3014001A1 CA3014001A CA3014001A CA3014001A1 CA 3014001 A1 CA3014001 A1 CA 3014001A1 CA 3014001 A CA3014001 A CA 3014001A CA 3014001 A CA3014001 A CA 3014001A CA 3014001 A1 CA3014001 A1 CA 3014001A1
Authority
CA
Canada
Prior art keywords
binding member
cancer
binding
cell
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3014001A
Other languages
English (en)
French (fr)
Inventor
Abdijapar SHAMSHIEV
Titus Kretzschmar
Miriam DROSTE
Douglas Phillips
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kuur Therapeutics Inc
Original Assignee
Cell Medica Switzerland AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cell Medica Switzerland AG filed Critical Cell Medica Switzerland AG
Publication of CA3014001A1 publication Critical patent/CA3014001A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/20—Vector systems having a special element relevant for transcription transcription of more than one cistron
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70532—B7 molecules, e.g. CD80, CD86

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
CA3014001A 2016-02-25 2017-02-24 Binding members to pd-l1 Pending CA3014001A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16020057.2 2016-02-25
EP16020057 2016-02-25
PCT/EP2017/054367 WO2017144681A1 (en) 2016-02-25 2017-02-24 Binding members to pd-l1

Publications (1)

Publication Number Publication Date
CA3014001A1 true CA3014001A1 (en) 2017-08-31

Family

ID=55446573

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3014001A Pending CA3014001A1 (en) 2016-02-25 2017-02-24 Binding members to pd-l1
CA3014067A Pending CA3014067A1 (en) 2016-02-25 2017-02-24 Modified cells for immunotherapy

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3014067A Pending CA3014067A1 (en) 2016-02-25 2017-02-24 Modified cells for immunotherapy

Country Status (12)

Country Link
US (3) US11434294B2 (enExample)
EP (3) EP4086285A1 (enExample)
JP (3) JP7080819B2 (enExample)
KR (2) KR20180111870A (enExample)
CN (3) CN116082505A (enExample)
AU (2) AU2017224843A1 (enExample)
BR (2) BR112018067696A2 (enExample)
CA (2) CA3014001A1 (enExample)
ES (1) ES2903408T3 (enExample)
RU (2) RU2018128464A (enExample)
SG (2) SG11201807187XA (enExample)
WO (2) WO2017147383A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110402892A (zh) * 2019-04-30 2019-11-05 梁廷波 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
EP4086285A1 (en) 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1
TWI786044B (zh) 2016-05-13 2022-12-11 美商再生元醫藥公司 藉由投予ｐｄ-１抑制劑治療皮膚癌之方法
GB201617714D0 (en) 2016-10-19 2016-11-30 Ucl Business Plc T Cell receptor
RS62865B1 (sr) 2016-12-08 2022-02-28 Immatics Biotechnologies Gmbh Novi t-ćelijski receptori i imunoterapija u kojoj se koriste
US11278570B2 (en) 2016-12-16 2022-03-22 B-Mogen Biotechnologies, Inc. Enhanced hAT family transposon-mediated gene transfer and associated compositions, systems, and methods
KR102523318B1 (ko) 2016-12-16 2023-04-18 비-모젠 바이오테크놀로지스, 인크. 증진된 ｈＡＴ 패밀리 트랜스포존 매개 유전자 전달 및 연관된 조성물, 시스템, 및 방법
KR20240011262A (ko) 2017-02-21 2024-01-25 리제너론 파아마슈티컬스, 인크. 폐암의 치료를 위한 항-pd-1 항체
JP2020516654A (ja) 2017-04-13 2020-06-11 センティ バイオサイエンシズ インコーポレイテッド 組み合わせがん免疫療法
AU2018258661A1 (en) 2017-04-28 2019-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides
CA3086187A1 (en) 2017-12-20 2019-06-27 Poseida Therapeutics, Inc. Vcar compositions and methods for use
CA3088832A1 (en) 2018-01-19 2019-07-25 Miltenyi Biotec B.V. & Co. KG Regulatory t cell expressing a chimeric antigen receptor
CN112119099A (zh) 2018-03-02 2020-12-22 Cdr-生物科技股份有限公司 三特异性抗原结合蛋白
CN112424225B (zh) * 2018-03-29 2023-08-11 桂林三金药业股份有限公司 抗pd-l1抗体及其用途
JP7518771B2 (ja) * 2018-06-04 2024-07-18 ディアテーバ ソチエタ レスポンサビリタ リミタータ 抗ｃｄ９９ダイアボディ又はｉｇｇ抗体及びそれらの使用
JP2021527427A (ja) 2018-06-21 2021-10-14 ビー−モーゲン・バイオテクノロジーズ，インコーポレーテッド 強化されたｈＡＴファミリーのトランスポゾンが介在する遺伝子導入ならびに関連する組成物、システム、及び方法
CN112119094B (zh) * 2018-06-29 2024-11-22 Y生物股份有限公司 与淋巴细胞活化基因3特异性结合的单克隆抗体及其用途
AU2019301070B2 (en) 2018-07-09 2025-09-11 Precigen, Inc. Fusion constructs and methods of using thereof
MX2021003744A (es) * 2018-10-01 2021-06-23 Adicet Bio Inc Composiciones y métodos relacionados con linfocitos t gamma delta modificados y no modificados para el tratamiento de tumores sólidos.
TW202035685A (zh) 2018-10-17 2020-10-01 美商聖堤生物科技股份有限公司 組合癌症免疫療法
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
US20210369776A1 (en) * 2018-12-06 2021-12-02 Guangdong Tcrcure Biopharma Technology Co., Ltd. Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints
WO2020135559A1 (en) * 2018-12-26 2020-07-02 Nanjing Legend Biotech Co., Ltd. Cd30-binding moieties, chimeric antigen receptors, and uses thereof
CN109652379B (zh) * 2018-12-29 2022-08-16 博生吉医药科技(苏州)有限公司 Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
CN111454358A (zh) * 2019-01-18 2020-07-28 四川科伦博泰生物医药股份有限公司 一种嵌合抗原受体及其应用
MX2021009020A (es) * 2019-01-28 2021-09-28 Xyphos Biosciences Inc Ligandos nkg2d no naturales modificados que entregan selectivamente moleculas heterologas unidas a receptores nkg2d no naturales en celulas car.
TW202045544A (zh) 2019-02-22 2020-12-16 美商戊瑞治療有限公司 用於治療ＰＤ－Ｌ１陰性腫瘤之ＣＤ８０胞外結構域Ｆｃ融合蛋白
CN113543792A (zh) * 2019-03-08 2021-10-22 奥托路斯有限公司 包含工程化嵌合抗原受体和car调节剂的组合物和方法
CA3134465A1 (en) * 2019-03-26 2020-10-01 The Regents Of The University Of California Chimeric antigen receptor modified t-cells (car-t) for the treatment of hematological and solid tumor cancers
CN118344479A (zh) * 2019-06-12 2024-07-16 苏州工业园区唯可达生物科技有限公司 Pd-l1靶向结合剂及其用途
MA56467A (fr) * 2019-07-02 2022-05-11 Telix Int Pty Ltd Anticorps dirigés contre caix avec une affinité réduite pour le récepteur fc néonatal
WO2021057906A1 (zh) * 2019-09-25 2021-04-01 科济生物医药（上海）有限公司 表达il-15的免疫效应细胞
JP2023500337A (ja) * 2019-11-04 2023-01-05 イノビオ ファーマシューティカルズ，インコーポレイティド 脳がんを治療するための併用療法
RU2733430C1 (ru) * 2019-11-19 2020-10-01 Общество с ограниченной ответственностью «Реал Таргет» Создание конъюгатов gd2-специфичных антител и фрагментов gd2-специфичных антител с препаратами
CN115925976A (zh) * 2019-11-21 2023-04-07 博生吉医药科技(苏州)有限公司 Cd7-car-t细胞及其制备和应用
AU2020396896A1 (en) * 2019-12-02 2022-06-09 Dana-Farber Cancer Institute, Inc. Antibodies against PD-L1 and methods of use thereof
WO2021130535A2 (en) * 2019-12-28 2021-07-01 Shanghai Cell Therapy Group Company Co., Ltd. Cell expressing immune modulatory molecules and system for expressing immune modulatory molecules
EP3878858A1 (en) * 2020-03-11 2021-09-15 Affilogic Variants of sac7d and their use in cancer therapy
CA3172932A1 (en) * 2020-03-23 2021-09-30 Curigin Co.,Ltd. Structure of oncolytic virus comprising bispecific nucleic acid molecule
CN115667292A (zh) * 2020-04-06 2023-01-31 朗格生物技术公共公益股份有限公司 模块化合成受体和使用方法
KR20230011948A (ko) * 2020-04-17 2023-01-25 더 카운실 오브 더 퀸즐랜드 인스티튜트 오브 메디컬 리서치 향상된 기능을 갖는 면역 세포
WO2021231975A1 (en) * 2020-05-14 2021-11-18 Virtuoso Binco, Inc. Humanized cd38 and icam1 antibodies and uses thereof
WO2021252654A1 (en) * 2020-06-11 2021-12-16 Innovative Cellular Therapeutics Holdings, Ltd. Cell/gene therapies targeting mage-a4 peptide
US20230227557A1 (en) * 2020-06-25 2023-07-20 Promab Biotechnologies, Inc. Pd-l1-specific antibody and anti-pd-l1-car-t cells
IL299764A (en) 2020-07-10 2023-03-01 Precigen Inc Fusion constructs and methods for using them
CA3197147A1 (en) * 2020-11-04 2022-05-12 Senti Biosciences, Inc. Protein payload release
CN112375743A (zh) * 2020-11-20 2021-02-19 山东省医学科学院附属医院 一种分泌型靶向her2抗原的嵌合抗原受体t细胞及其应用
JP2023551482A (ja) * 2020-11-30 2023-12-08 フレッド ハッチンソン キャンサー センター Ｐｄ－ｌ１結合ペプチド及びペプチド複合体及びそれらの使用方法
EP4323389A1 (en) * 2021-04-15 2024-02-21 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft T-cell receptors specific for both rac1- and rac2-derived mutated epitopes
CN113234152B (zh) * 2021-06-03 2023-05-02 天津科技大学 程序性死亡受体-配体1(pd-l1)特异性结合多肽及应用
WO2023274387A1 (zh) * 2021-07-01 2023-01-05 宁波茂行生物医药科技有限公司 靶向gd2的通用型car-t细胞及其制备方法和应用
EP4376887A4 (en) * 2021-07-30 2025-09-24 Janssen Biotech Inc MATERIALS AND METHODS FOR MAKING OR USING IL-23 R BINDING PROTEINS
MX2024001948A (es) 2021-08-13 2024-05-17 Inovio Pharmaceuticals Inc Terapia combinada para tratar el cáncer cerebral.
CN118176017A (zh) * 2021-10-26 2024-06-11 正大天晴药业集团股份有限公司 治疗肿瘤的联用药物
CN116410331B (zh) * 2021-12-31 2024-01-30 合源生物科技(天津)有限公司 靶向cs1的嵌合抗原受体、靶向bcma/cs1的双特异性嵌合抗原受体及其应用
EP4469069A4 (en) * 2022-01-28 2026-05-06 Univ North Carolina Chapel Hill T LYMPHOCYTES, NATURAL KILLERS, AND THEIR METHODS OF USE
CN118005806B (zh) * 2024-02-08 2026-01-30 北京市眼科研究所 嵌合抗原受体、人多能干细胞分化的表达嵌合抗原受体的小胶质细胞及其应用
CN120518751B (zh) * 2025-07-23 2025-09-19 中国人民解放军军事科学院军事医学研究院 抗人4型腺病毒特异性纳米抗体lum44及在抗病毒治疗中的应用

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4237113B4 (de) 1992-11-03 2006-10-12 "Iba Gmbh" Peptide und deren Fusionsproteine, Expressionsvektor und Verfahren zur Herstellung eines Fusionsproteins
DE19641876B4 (de) 1996-10-10 2011-09-29 Iba Gmbh Streptavidinmuteine
DE10113776B4 (de) 2001-03-21 2012-08-09 "Iba Gmbh" Isoliertes streptavidinbindendes, kompetitiv eluierbares Peptid, dieses umfassendes Fusionspeptid, dafür codierende Nukleinsäure, Expressionsvektor, Verfahren zur Herstellung eines rekombinanten Fusionsproteins und Verfahren zum Nachweis und/oder zur Gewinnung des Fusionsproteins
US20040241745A1 (en) 2001-07-31 2004-12-02 Tasuku Honjo Substance specific to pd-1
PT2332989E (pt) 2002-05-22 2015-08-05 Esbatech Alcon Biomed Res Unit Estruturas de imunoglobulina que demonstram estabilidade aumentada no ambiente intracelular e métodos de identificação das mesmas
GB0328363D0 (en) 2003-12-06 2004-01-14 Imp College Innovations Ltd Therapeutically useful molecules
JP5563194B2 (ja) 2004-06-29 2014-07-30 イムノコア リミテッド 改変ｔ細胞レセプターを発現する細胞
CA2612241C (en) * 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
CA2947292C (en) 2006-12-27 2019-07-23 Emory University Compositions and methods for the treatment of infections and tumors
DK2158315T3 (en) 2007-06-25 2016-06-06 Esbatech Alcon Biomed Res Unit Methods of modifying antibodies and modified antibodies with improved functional properties
HUE038432T2 (hu) 2008-06-25 2018-10-29 Esbatech Alcon Biomed Res Unit Nyúl antitestek humanizálása egy univerzális antitest keret alkalmazásával
US9556265B2 (en) 2008-06-25 2017-01-31 Esbatech, An Alcon Biomedical Research Unit Llc Solubility optimization of immunobinders
EP4209510B1 (en) * 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
NO2504364T3 (enExample) 2009-11-24 2018-01-06
WO2012033885A1 (en) 2010-09-08 2012-03-15 Baylor College Of Medicine Immunotherapy of cancer using genetically engineered gd2-specific t cells
EP2755487B1 (en) 2011-09-16 2018-12-19 Baylor College Of Medicine Targeting the tumor microenvironment using manipulated nkt cells
US9624298B2 (en) 2011-11-28 2017-04-18 Merck Patent Gmbh Anti-PD-L1 antibodies and uses thereof
AU2013267161A1 (en) * 2012-05-31 2014-11-20 Sorrento Therapeutics, Inc. Antigen binding proteins that bind PD-L1
BR112014030750A2 (pt) * 2012-06-06 2017-08-22 Inst Catalana Recerca Estudis Avancats Método para diagnóstico, prognóstico e tratamento da metástase do câncer pulmonar
BR112015020516A2 (pt) * 2013-02-26 2017-10-10 Memorial Sloan Kettering Cancer Center composições e métodos para imunoterapia
CA2914829A1 (en) 2013-06-26 2014-12-31 Numab Therapeutics AG Novel antibody frameworks
WO2015038538A1 (en) 2013-09-10 2015-03-19 Medimmune, Llc Compositions and methods for treating sepsis
EP3074025A1 (en) 2013-11-27 2016-10-05 Baylor College Of Medicine Csgp4-specific chimeric antigen receptor for cancer
TWI680138B (zh) * 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
EP3593812A3 (en) * 2014-03-15 2020-05-27 Novartis AG Treatment of cancer using chimeric antigen receptor
EP3151854B1 (en) * 2014-06-06 2020-02-26 Memorial Sloan Kettering Cancer Center Mesothelin-targeted chimeric antigen receptors and uses thereof
BR112017000497B1 (pt) * 2014-07-11 2023-12-26 Ventana Medical Systems, Inc Anticorpo isolado, célula hospedeira procariótica, imunoconjugado e método de detecção da presença ou do nível de expressão de pd-l1
CA2959694C (en) 2014-09-04 2023-11-21 Cellectis Trophoblast glycoprotein (5t4, tpbg) specific chimeric antigen receptors for cancer immunotherapy
EP3858991A1 (en) 2014-09-26 2021-08-04 Baylor College of Medicine Glypican-3 specific chimeric antigen receptors for adoptive immunotherapy
WO2016070119A1 (en) 2014-10-31 2016-05-06 Baylor College Of Medicine Survivin specific t-cell receptor targeting tumor but not t cells
KR102923234B1 (ko) 2014-12-19 2026-02-04 다나-파버 캔서 인스티튜트 인크. 키메라 항원 수용체 및 이의 사용 방법
GB201506642D0 (en) 2015-04-20 2015-06-03 Ucl Business Plc T cell receptor
CN105331585A (zh) * 2015-11-13 2016-02-17 科济生物医药（上海）有限公司 携带pd-l1阻断剂的嵌合抗原受体修饰的免疫效应细胞
EP4086285A1 (en) * 2016-02-25 2022-11-09 Cell Medica Switzerland AG Binding members to pd-l1

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110402892A (zh) * 2019-04-30 2019-11-05 梁廷波 选择性敲除胰腺上皮细胞程序性死亡配体1分子的自发胰腺癌小鼠模型的建立方法

Also Published As

Publication number Publication date
JP2022116230A (ja) 2022-08-09
WO2017147383A8 (en) 2018-11-15
CA3014067A1 (en) 2017-08-31
JP7082574B2 (ja) 2022-06-08
EP3420000A1 (en) 2019-01-02
ES2903408T3 (es) 2022-04-01
AU2017223846A1 (en) 2018-08-23
WO2017144681A1 (en) 2017-08-31
KR20190003938A (ko) 2019-01-10
JP2019515646A (ja) 2019-06-13
SG11201807187XA (en) 2018-09-27
CN108884164A (zh) 2018-11-23
RU2018128462A (ru) 2020-03-25
CN108699153B (zh) 2022-09-23
CN116082505A (zh) 2023-05-09
CN108884164B (zh) 2022-12-27
US11434294B2 (en) 2022-09-06
US20230235061A1 (en) 2023-07-27
US20190048085A1 (en) 2019-02-14
BR112018067698A2 (pt) 2019-01-08
WO2017147383A1 (en) 2017-08-31
RU2018128464A (ru) 2020-03-25
KR20180111870A (ko) 2018-10-11
JP7080819B2 (ja) 2022-06-06
JP2019513009A (ja) 2019-05-23
EP4086285A1 (en) 2022-11-09
AU2017224843A1 (en) 2018-08-23
US20190055312A1 (en) 2019-02-21
EP3420001B1 (en) 2021-12-01
SG11201807188VA (en) 2018-09-27
EP3420001A1 (en) 2019-01-02
BR112018067696A2 (pt) 2019-01-08
CN108699153A (zh) 2018-10-23

Similar Documents

Publication Publication Date Title
US20230235061A1 (en) Binding Members to PD-L1
KR102629403B1 (ko) Vista 항원 결합 분자
US10995138B2 (en) Nucleic acids encoding binding members to TNF alpha
KR102593409B1 (ko) Her3 항원 결합 분자
US11873346B2 (en) VISTA antigen-binding molecules
EP3778648A1 (en) Novel antibody molecule, and preparation method and use thereof
JP2021521784A (ja) ＩＬ−１５／ＩＬ−１５ＲａＦｃ融合タンパク質とＰＤ−１抗原結合ドメインを含むＰＤ−１標的化ヘテロダイマー融合タンパク質およびそれらの使用
KR20240055080A (ko) Pd-1에 특이적으로 결합하는 단백질 및 그의 약학적 용도
HK40002298B (en) Binding members to pd-l1
RU2795625C2 (ru) Антигенсвязывающие белки против gitr и способы их применения
HK40026638A (en) Vista antigen-binding molecules
HK40026638B (en) Vista antigen-binding molecules

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251222

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260223

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260407